Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder

Journal of Clinical Psychiatry

Volumn 74, Issue 10, 2013, Pages 1010-1017

  Clayton, Anita H ^a   Kornstein, Susan G ^c   Dunlop, Boadie W ^b   Focht, Kristen ^d   Musgnung, Jeff ^d   Ramey, Tanya ^d   Bao, Weihang ^d   Ninan, Philip T ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; AGED; ANORGASMIA; ARTICLE; CLIMACTERIUM; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HAMILTON SCALE; HEADACHE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SHEEHAN DISABILITY SCALE; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84887102091     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08065     Document Type: Article

References (39)

1. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74(1):5-13. (Pubitemid 36329172)
2. Deecher D, Andree TH, Sloan D, et al From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology. 2008;33(1):3-17.
3. Clayton AH, Ninan PT Depression or menopause? presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry. 2010;12(1):e1-e13.
4. Santoro N, Brown JR, Adel T, et al Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81(4):1495-1501. (Pubitemid 26118582)
5. Freeman E.W., Sammel MD, Liu L, et al Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61(1):62-70. (Pubitemid 38044642)
6. Graziottin A, Serafini A. Depression and the menopause: why antidepressants are not enough? Menopause Int. 2009;15(2):76-81.
7. Thase ME, Entsuah R, Cantillon M., et al Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005;14(7):609-616. (Pubitemid 41488679)
8. Grigoriadis S, Kennedy SH, Bagby RM A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol. 2003;23(4):405-407. (Pubitemid 36951184)
9. Martényi F., Dossenbach M, Mraz K., et al Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychophar macol. 2001;11(3):227-232. (Pubitemid 32618645)
10. Rossouw JE, Anderson GL, Prentice R.L., et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-333. (Pubitemid 34761611)
11. Soares CN, Almeida OP, Joffe H, et al Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001; 58(6):529-534. (Pubitemid 32523731)
12. Morrison MF, Kallan MJ, Ten Have T, et al Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55(4):406-412. (Pubitemid 38199991)
13. Scali J, Ryan J, Carrière I, et al A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study J Clin Psychiatry. 2010;71(12):1673-1679.
14. Rossouw JE, Prentice RL, Manson J.E., et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. (Pubitemid 46556472)
15. Shumaker SA, Legault C, Rapp S.R., et al.; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20): 2651-2662. (Pubitemid 37430136)
16. Altshuler LL, Cohen LS, Moline M.L., et al.; Expert Consensus Panel for Depression in Women. The Expert Consensus Guideline Series: treatment of depression in women. Postgrad Med. 2001;(Spec No):1-107. PubMed
17. Shansky RM, Bender G, Arnsten AF Estrogen prevents norepinephrine alpha-2a receptor reversal of stress-induced working memory impairment. Stress. 2009;12(5):457-463.
18. Rasgon NL, Dunkin J, Fairbanks L., et al Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. J Psychiatr Res. 2007;41(3-4):338-343. (Pubitemid 44854988)
19. Zanardi R, Rossini D, Magri L., et al Response to SSRIs and role of the hormonal therapy in post-menopausal depression. Eur Neuropsychophar macol. 2007;17(6-7):400-405. (Pubitemid 46497659)
20. Kornstein SG, Schatzberg AF, Thase M.E., et al Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445-1452.
21. Joffe H, Soares CN, Petrillo L.F., et al Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68(6):943-950. (Pubitemid 47015497)
22. Reddy S, Kane C, Pitrosky B., et al Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010;26(1):139-150.
23. Seo HJ, Sohi MS, Patkar A.A., et al Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Postgrad Med. 2010;122(1):125-138.
24. Kornstein SG, Jiang Q, Reddy S., et al Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71(8):1088-1096.
25. US Department of Commerce Economics and Statistics Administration. Census Regions and Divisions of the United States. http://www.census.gov/geo/www/us- regdiv.pdf. Accessed October 4, 2012.
26. Sheehan DV, Lecrubier Y, Sheehan K.H., et al The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20):22-33, quiz 34-57. (Pubitemid 29001829)
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to ch ange. Br J Psychiatry. 1979;134(4):382-389. (Pubitemid 9136500)
28. Bech P, Allerup P, Gram L.F., et al The Hamilton depression scale: evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63(3):290-299. (Pubitemid 11137960)
29. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institue of Mental Health; 1976:217-222.
30. Rush AJ, Trivedi MH, Ibrahim H.M., et al The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
31. DeLoach LJ, Higgins MS, Caplan A.B., et al The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998;86(1):102-106. (Pubitemid 28040099)
32. Sheehan DV, Harnett-Sheehan K, Raj BA The measurement of disability. Int C lin Psychopharmacol. 1996;11(SUPPL. 3):89-95. (Pubitemid 26373761)
33. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199-208.
34. Heinemann K, Ruebig A, Potthoff P., et al The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004;2(1):45.
35. Posner K, Brown GK, Stanley B, et al The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
36. Cohen LS, Soares CN, Vitonis A.F., et al Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385-390.
37. Freeman EW, Sammel MD, Lin H, et al Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375-382.
38. Cheng RJ, Dupont C, Archer D.F., et al Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2013;16(1):17-27.
39. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663-1672. (Pubitemid 350247495)